Oncternal Therapeutics Inc (ONCT) - News Archive

Oncternal Therapeutics Halts Clinical Trials, Explores Strategic Alternatives Amid Continued Financial StrugglesBy Author NamennSAN DIEGO, Sept. 12, 2024nn Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage b...

Advancing Treatment for Metastatic Castration-Resistant Prostate Cancer: Oncternal s Progress with ONCT-534Oncternal Therapeutics, a renowned clinical-stage biopharmaceutical company focused on developing innovative onc...

Oncternal Advances Phase 1/2 Study of ONCT-534 for Treatment of Metastatic Castration-Resistant Prostate CancerOncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in the development of...

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) has recently approved an inducement award for Anne C. Hansen, who is joining the company as Senior Director, Clinical Data Management. This news comes on the heels of the comp...

The preeminent biopharmaceutical entity, Oncternal Therapeutics, has constantly pushed the bounds of innovation in its dogged pursuit of creating novel oncology therapies. The burgeoning clinical-stage biotech announced...

In a recent press release, Oncternal Therapeutics, a prominent clinical-stage biopharmaceutical company specializing in the development of innovative oncology therapies, announced the approval of an inducement award for...

On January 4, 2024, Oncternal Therapeutics, a clinical-stage biopharmaceutical company specializing in the development of oncology therapies, announced a reverse stock split. The company s board of directors has approve...

In recent years, immunotherapy has emerged as a groundbreaking approach in the field of oncology, offering new hope for patients with cancer. Oncternal Therapeutics, a clinical-stage biopharmaceutical company, has demon...